Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific

A. S. Kadish, S. L. Romney, R. Ledwidge, R. Tindle, G. J P Fernando, S. Y. Zee, M. A. Van Ranst, Robert D. Burk

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Forty-two women attending a colposcopy clinic for evaluation of abnormal cervical cytology and 13 normal controls were studied for the presence of lymphocyte proliferation (LP) cell-mediated immune (CMI) responses and serological reactivity to E7 peptides of human papillomavirus type 16 (HPV-16). HPV was typed by Southern blot hybridization of exfoliated cervicovaginal cell DNA. Positive LP responses (stimulation index ≥ 5.0) to one or more E7 peptides were observed in 28.6% (12 of 42) of patients and 23.1% (three of 13) of controls. Of patients infected with HPV-16, -31 or -33, 63.6% (seven of 11) showed a positive LP response compared with 14.3% (two of 14) of women infected with other HPV types (P = 0.02), 17.6% (three of 17) negative for HPV (P = 0.02) and 23.1% (three of 13) of controls (HPV status unknown) (P = 0.05). C-terminal peptide 109 (amino acids 72 to 97) elicited positive LP responses in 45.4% (five of 11) of patients infected with HPV-16, -31 or -33 compared with 7.1% (one of 14) patients infected with other HPVs (P = 0.04), 5.9% (one of 17) of women negative for HPV (P = 0.02) and 7.7% (one of 13) of controls (P = 0.05). HPV-16 group-specific LP responses of borderline significance were also observed against E7 peptides 103, 105 and 108 (17-37, 37-54 and 62-80) (P = 0.07). ELISA reactivity (IgG) to E7 peptide 109 (72-97) was present in 7.7% (one of 13) of controls, 35.3% (six of 17) of HPV-negative patients, 42.9% (six of 14) of patients infected with other HPVs, and only 9.1% (one of 11) of patients infected with HPV-16, -31 or -33. CMI responses to C-terminal HPV-16 E7 peptide 109 (72-97) were thus significantly related to ongoing cervical infection with HPV-16 and closely related types, whereas serological reactivity to E7 peptides was not HPV type-specific.

Original languageEnglish (US)
Pages (from-to)2277-2284
Number of pages8
JournalJournal of General Virology
Volume75
Issue number9
StatePublished - 1994

Fingerprint

Human papillomavirus 16
Cervix Uteri
Human papillomavirus 31
Peptides
Lymphocytes
Colposcopy
Southern Blotting
Cell Biology
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Cell Proliferation
Amino Acids
DNA
Infection

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. / Kadish, A. S.; Romney, S. L.; Ledwidge, R.; Tindle, R.; Fernando, G. J P; Zee, S. Y.; Van Ranst, M. A.; Burk, Robert D.

In: Journal of General Virology, Vol. 75, No. 9, 1994, p. 2277-2284.

Research output: Contribution to journalArticle

Kadish, A. S. ; Romney, S. L. ; Ledwidge, R. ; Tindle, R. ; Fernando, G. J P ; Zee, S. Y. ; Van Ranst, M. A. ; Burk, Robert D. / Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. In: Journal of General Virology. 1994 ; Vol. 75, No. 9. pp. 2277-2284.
@article{2c0c630aa70d47a68ad96dde7700765b,
title = "Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific",
abstract = "Forty-two women attending a colposcopy clinic for evaluation of abnormal cervical cytology and 13 normal controls were studied for the presence of lymphocyte proliferation (LP) cell-mediated immune (CMI) responses and serological reactivity to E7 peptides of human papillomavirus type 16 (HPV-16). HPV was typed by Southern blot hybridization of exfoliated cervicovaginal cell DNA. Positive LP responses (stimulation index ≥ 5.0) to one or more E7 peptides were observed in 28.6{\%} (12 of 42) of patients and 23.1{\%} (three of 13) of controls. Of patients infected with HPV-16, -31 or -33, 63.6{\%} (seven of 11) showed a positive LP response compared with 14.3{\%} (two of 14) of women infected with other HPV types (P = 0.02), 17.6{\%} (three of 17) negative for HPV (P = 0.02) and 23.1{\%} (three of 13) of controls (HPV status unknown) (P = 0.05). C-terminal peptide 109 (amino acids 72 to 97) elicited positive LP responses in 45.4{\%} (five of 11) of patients infected with HPV-16, -31 or -33 compared with 7.1{\%} (one of 14) patients infected with other HPVs (P = 0.04), 5.9{\%} (one of 17) of women negative for HPV (P = 0.02) and 7.7{\%} (one of 13) of controls (P = 0.05). HPV-16 group-specific LP responses of borderline significance were also observed against E7 peptides 103, 105 and 108 (17-37, 37-54 and 62-80) (P = 0.07). ELISA reactivity (IgG) to E7 peptide 109 (72-97) was present in 7.7{\%} (one of 13) of controls, 35.3{\%} (six of 17) of HPV-negative patients, 42.9{\%} (six of 14) of patients infected with other HPVs, and only 9.1{\%} (one of 11) of patients infected with HPV-16, -31 or -33. CMI responses to C-terminal HPV-16 E7 peptide 109 (72-97) were thus significantly related to ongoing cervical infection with HPV-16 and closely related types, whereas serological reactivity to E7 peptides was not HPV type-specific.",
author = "Kadish, {A. S.} and Romney, {S. L.} and R. Ledwidge and R. Tindle and Fernando, {G. J P} and Zee, {S. Y.} and {Van Ranst}, {M. A.} and Burk, {Robert D.}",
year = "1994",
language = "English (US)",
volume = "75",
pages = "2277--2284",
journal = "Journal of General Virology",
issn = "0022-1317",
publisher = "Society for General Microbiology",
number = "9",

}

TY - JOUR

T1 - Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific

AU - Kadish, A. S.

AU - Romney, S. L.

AU - Ledwidge, R.

AU - Tindle, R.

AU - Fernando, G. J P

AU - Zee, S. Y.

AU - Van Ranst, M. A.

AU - Burk, Robert D.

PY - 1994

Y1 - 1994

N2 - Forty-two women attending a colposcopy clinic for evaluation of abnormal cervical cytology and 13 normal controls were studied for the presence of lymphocyte proliferation (LP) cell-mediated immune (CMI) responses and serological reactivity to E7 peptides of human papillomavirus type 16 (HPV-16). HPV was typed by Southern blot hybridization of exfoliated cervicovaginal cell DNA. Positive LP responses (stimulation index ≥ 5.0) to one or more E7 peptides were observed in 28.6% (12 of 42) of patients and 23.1% (three of 13) of controls. Of patients infected with HPV-16, -31 or -33, 63.6% (seven of 11) showed a positive LP response compared with 14.3% (two of 14) of women infected with other HPV types (P = 0.02), 17.6% (three of 17) negative for HPV (P = 0.02) and 23.1% (three of 13) of controls (HPV status unknown) (P = 0.05). C-terminal peptide 109 (amino acids 72 to 97) elicited positive LP responses in 45.4% (five of 11) of patients infected with HPV-16, -31 or -33 compared with 7.1% (one of 14) patients infected with other HPVs (P = 0.04), 5.9% (one of 17) of women negative for HPV (P = 0.02) and 7.7% (one of 13) of controls (P = 0.05). HPV-16 group-specific LP responses of borderline significance were also observed against E7 peptides 103, 105 and 108 (17-37, 37-54 and 62-80) (P = 0.07). ELISA reactivity (IgG) to E7 peptide 109 (72-97) was present in 7.7% (one of 13) of controls, 35.3% (six of 17) of HPV-negative patients, 42.9% (six of 14) of patients infected with other HPVs, and only 9.1% (one of 11) of patients infected with HPV-16, -31 or -33. CMI responses to C-terminal HPV-16 E7 peptide 109 (72-97) were thus significantly related to ongoing cervical infection with HPV-16 and closely related types, whereas serological reactivity to E7 peptides was not HPV type-specific.

AB - Forty-two women attending a colposcopy clinic for evaluation of abnormal cervical cytology and 13 normal controls were studied for the presence of lymphocyte proliferation (LP) cell-mediated immune (CMI) responses and serological reactivity to E7 peptides of human papillomavirus type 16 (HPV-16). HPV was typed by Southern blot hybridization of exfoliated cervicovaginal cell DNA. Positive LP responses (stimulation index ≥ 5.0) to one or more E7 peptides were observed in 28.6% (12 of 42) of patients and 23.1% (three of 13) of controls. Of patients infected with HPV-16, -31 or -33, 63.6% (seven of 11) showed a positive LP response compared with 14.3% (two of 14) of women infected with other HPV types (P = 0.02), 17.6% (three of 17) negative for HPV (P = 0.02) and 23.1% (three of 13) of controls (HPV status unknown) (P = 0.05). C-terminal peptide 109 (amino acids 72 to 97) elicited positive LP responses in 45.4% (five of 11) of patients infected with HPV-16, -31 or -33 compared with 7.1% (one of 14) patients infected with other HPVs (P = 0.04), 5.9% (one of 17) of women negative for HPV (P = 0.02) and 7.7% (one of 13) of controls (P = 0.05). HPV-16 group-specific LP responses of borderline significance were also observed against E7 peptides 103, 105 and 108 (17-37, 37-54 and 62-80) (P = 0.07). ELISA reactivity (IgG) to E7 peptide 109 (72-97) was present in 7.7% (one of 13) of controls, 35.3% (six of 17) of HPV-negative patients, 42.9% (six of 14) of patients infected with other HPVs, and only 9.1% (one of 11) of patients infected with HPV-16, -31 or -33. CMI responses to C-terminal HPV-16 E7 peptide 109 (72-97) were thus significantly related to ongoing cervical infection with HPV-16 and closely related types, whereas serological reactivity to E7 peptides was not HPV type-specific.

UR - http://www.scopus.com/inward/record.url?scp=0028015931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028015931&partnerID=8YFLogxK

M3 - Article

C2 - 8077925

AN - SCOPUS:0028015931

VL - 75

SP - 2277

EP - 2284

JO - Journal of General Virology

JF - Journal of General Virology

SN - 0022-1317

IS - 9

ER -